BioInvent conducts research and development in cooperation with a number of partners, both in the pharmaceutical industry – often with leading international biotech and pharmaceutical companies – and academic institutions. Collaborations create opportunities for working with the world's most prominent experts and is crucial to our success.

Sharing our knowledge base and specialist expertise in antibody research with world leading partners in order to generate revenues is a key part of our strategy and business model. We continually seek partnerships and collaborations to expand our knowledge and to establish additional commercial opportunities. We can provide access to our technology platforms as well as perform research to meet the needs of our partners.

BioInvent’s scientific expertise and technologies within the field of antibodies have been validated through its partnerships with pharmaceutical companies in Europe and Japan. Presently, we have collaborations with Bayer Pharma, Daiichi Sankyo, Mitsubishi Tanabe Pharma and Servier, as well as on-going discussions with a number of potential partners.

BioInvent also collaborates with research groups at the University of Southampton and Cancer Research Technology.

The terms of the collaborations vary but generally BioInvent receives licence fees and research financing as well as milestone payments and royalties of sales of commercial products.